The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Razumova I.Yu.

Research Institute of Eye Diseases

Godzenko A.A.

Russian Medical Academy of Continuous Professional Education

New possibilities in therapy of ocular inflammation in rheumatic diseases

Authors:

Razumova I.Yu., Godzenko A.A.

More about the authors

Journal: Russian Annals of Ophthalmology. 2022;138(6): 108‑114

DOI: 10.17116/oftalma2022138061108

Read: 3458 times

Download PDF (RU)
Contact the author
Table of contents

NEW POSSIBILITIES IN THERAPY OF OCULAR INFLAMMATION IN RHEUMATIC DISEASES
NEW POSSIBILITIES IN THERAPY OF OCULAR INFLAMMATION IN RHEUMATIC DISEASES

To cite this article:

Razumova IYu, Godzenko AA. New possibilities in therapy of ocular inflammation in rheumatic diseases. Russian Annals of Ophthalmology. 2022;138(6):108‑114. (In Russ.)
https://doi.org/10.17116/oftalma2022138061108

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Role of doctor-patient communication in rheumatology. Russian Journal of Preventive Medi­cine. 2025;(4):156-161
Biomarkers in tear fluid in uveitis. Russian Annals of Ophthalmology. 2025;(4):88-95
Abstract:

This review is devoted to the potential application of genetically engineered biological drugs of different classes in the treatment of main forms of uveitis and other types of non-infectious ocular inflammation in immunoinflammatory rheumatic diseases. The article presents the results of studies demonstrating the influence of interleukin-17 inhibitor secukinumab on the course of uveitis in spondylarthritis, shows the possibilities of treating uveitis in juvenile idiopathic arthritis with inhibitors of interleukin-6, co-stimulation of T-lymphocytes. Inhibition of interleukin-1 is considered an effective method of influencing the ocular inflammation in monogenic autoinflammatory syndromes and Behcet’s disease. Rituximab is considered as an option for immunosuppressive therapy of non-infectious uveitis and scleritis.

Keywords:

uveitis
scleritis
episcleritis
rheumatic diseases
interleukin inhibitors

Authors:

Razumova I.Yu.

Research Institute of Eye Diseases

Godzenko A.A.

Russian Medical Academy of Continuous Professional Education

Received:

06.12.2021

Accepted:

25.03.2022

Close metadata

References:

  1. Nasonov EL, Denisov LN, Stanislav ML. Interleukin 17 is a New Target for anti-cytokine Therapy of Immune Inflammatory Rheumatic Diseases. Nauchno-prakticheskaya revmatologiya. 2013;51(5):545-552. (In Russ.).
  2. Ceribelli A, Motta F, Vecellio M, Isailovic N, Ciccia F, Selmi C. Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis. Front Immunol. 2021;12:622770. https://doi.org/10.3389/fimmu.2021.622770
  3. Guedes MC, Borrego LM, Proença RD. Roles of interleukin 17 in uveitis. Indian J Ophthalmol. 2016;64(9):628-634.  https://doi.org/10.4103/0301-4738.194339
  4. Hueber W, Patel DD, Dryia T, Wright A, Koroleva I, Bruin G, Antoni Ch, Draelos Z, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010; 2(52):52ra72. https://doi.org/10.1126/scitranslmed.3001107
  5. Letko E, Yen S, Foster GS, Pleyer U, Brigell M, Grosskreitz CL. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive. J Ophthalmol. 2015;122(5):939-948.  https://doi.org/1016/j.ophtha 2014.12.033
  6. Braun J, Baraliakos X, Deodhar A, Baeten D, Stepper J, Emery P, Readie A, Martin R, Mpofu S, Richards H. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76(6):1070-1077. https://doi.org/10.1136/annrheumdis-2016-209730
  7. Deodhar A, Miceli-Richard C, Baraliakos X, Marzo-Ortega H, Gladman DD, Blanco R, Gupta AD, Martin R, Safi Jr J, Porter B, Shete A, Rosenbaum JT. Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. ACR Open Rheumatol. 2020;2(5):294-299.  https://doi.org/10.1002/acr2.11139
  8. Lindström U, Bengtsson K, Olofsson T, Di Giuseppe D, Glintborg B, Forsblad-d’Elia H, Jacobsson LTH, Askling J. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter? Ann Rheum Dis. 2021;80(11):1445-1452. https://doi.org/10.1136/annrheumdis-2021-220420
  9. Tsang AC, Roth J, Gottlieb C. Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm. 2014;22:155-157.  https://doi.org/10.3109/09273948 2013 866254
  10. Tappeiner C, Mesquida M, Adan A, Anton J, Romanan AV, Carreno E, Mackensen F, Kotaniemi K, deBoer JH, Bou R, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43:2183-2188. https://doi.org/103899/j.rheum 160231
  11. Calvo-Río V, Santos-Gómez M, Calvo I, González-Fernández MI, López-Montesinos B, Mesquida M, Adán A, Hernández MV, Maíz O, Atanes A, Bravo B, Modesto C, Díaz-Cordovés G, Palmou-Fontana N, et al. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. Arthritis Rheum. 2017;69(3): 668-675.  https://doi.org/10.1002/art.39940
  12. Bunchuk NV. Gigantokletochnyy arteriit i revmaticheskaya polimialgiya [On giant cell arteritis and rheumatic polymyalgia]. M.: Erus; 1992;156. (In Russ.).
  13. Salvarani C, Cantini F, Boiardi L, Hunder G. Laboratory investigations useful in giant cell arteritis and Takayasu’s arteritis. Clin Exp Rheumatol. 2003; 21(6 suppl 32):23-28. 
  14. Pulsatelli L, Boiardi L, Assirelli E, Pazzola G, Muratore F, Addimanda O, Dolzani B, Vorsan F, Casali M, et al. Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study. Clin Exp Rheumatol. 2017;35 suppl 103(1):102-110. 
  15. Beketova TV, Ushakova MA, Nikishina NYu, Khelkovskaya-Sergeeva AN, Nikolaeva EN, Sazhina EG, Novoselova TM, Nasonov EL. Experience with tocilizumab, an interleukin 6 inhibitor, used for the treatment of giant cell arteritis with severe comorbidity. Nauchno-prakticheskaya revmatologiya. 2018;56(2):228-234. (In Russ.). https://doi.org/10/14412/1995-4484-2018-228-234
  16. Stone JH, Tuckwell K, Dimonaco S, Klerman M, Aringer M, Blockmans D, Brouver E, Cid MC, Dasgupta B, Rech S, Salvaroni C, Spiera RF, Unizom SH, Collinson N. Efficacy and safety of tocilizumab in patients with giant cell arteritis: Primary and secondary outcomes from a phase 3, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2016;68(10):abstr.911. 
  17. Regola F, Cerudelli E, Bosio G, Andreoli L, Tincani A, Franceschini F, Toniati P. Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients. Rheumatol Adv Pract. 2020; 4(2):rkaa017. eCollection 2020. https://doi.org/10.1093/rap/rkaa017
  18. Schett G, Dayer JM, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol. 2016;12(1):14-24.  https://doi.org/10.1038/nrrheum 2016.166
  19. Wakefield D, Di Girolamo N, Thurau S, Wildner G, McCluskey P. Scleritis: Immunopathogenesis and molecular basis for therapy. Prog Retin Eye Res. 2013;16(88):153-157.  https://doi.org/10.1016/jpreteyeres 2013.02.004
  20. Tugal-Tutkun I, Pavesio C, De Cordoue A, Bernard-Poenaru O. Use of gevokizumab in patients with Behcet’s disease uveitis: an international, randomized, double-masked, placebo-controlled study and openlabel extension study. Ocul Immunol Inflamm. 2018;25:1-11.  https://doi.org/10.1080/09273948.2017.1421233
  21. Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, Gentileschi S, Bacherini D, Franceschini R, Frediani B, Galeazzi M, Iannone F, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):191-197. Epub 2016 Dec 16.  https://doi.org/10.1007/s10067-016-3506-4
  22. Knickelbein JE, Tucker WR, Bhatt N, Armbrust K, Valent D, Obiyor D, Nussenblatt RB, Sen HN. Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial. Am J Ophthalmol. 2016;172:104-110.  https://doi.org/10.1016/j.ajo.2016.09.017
  23. Muckle TJ, Wellsm. Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. Q J Med. 1962;31:235-248. 
  24. Cekic S, Yalcinbayir O, Kilic SS. Ocular Involvement in Muckle-Wells Syndrome. Ocul Immunol Inflamm. 2020;28(1):70-78. Epub 2018. https://doi.org/10.1080/09273948.2018.1552305
  25. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin IB, Kim HJ, Brewet C, Zalewwsky C, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006;355(6):581-592.  https://doi.org/10.1056/NEJM oa.055.137/
  26. Lepore L, Paloni G, Caorsi R, Alessio M, Rigante D, Ruperto N, Cattalini M, Tommasini A, Zulian F, Ventura A, Martini A, Gatorno M. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr. 2010;157(2):310-315.  https://doi.org/10.1016/j.jpeds 2010.02.040
  27. Yokota S, Imagawa T, Nishikomori R, Takada H, Abrams K, Lheritier K, Heike T, Hara T. Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients. Clin Exp Rheumatol. 2017;108(6):19-26. 
  28. Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70(12):2095-2102. https://doi.org/10.1036/ard 2011.152-728
  29. Kim L, Li A, Angeles-Han S, Yeh S, Shautha JS. Update on the management of uveitis in children: an overview for the clinician. Exp Rev Ophthalmol. 2019;14(4-5):211-218.  https://doi.org/10.1080/17469899.2019.1663731
  30. Birolo C, Zannin ME, Arsenyeva S, Cimaz R, Miserocchi E, Dubko M, Deslandre CJ, Falcini F, Alessio M, La Torre F, Denisova E, Martini G, Nikishina I, Zulian F. Comparable Efficacy of Abatacept Used as First-line or Second-line Biological Agent for Severe Juvenile Idiopathic Arthritis-related Uveitis. J Rheumatol. 2016;43(11):2068-2073. Epub 2016 Sep 15.  https://doi.org/10.3899/jrheum.151389
  31. Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis. 2013;72(2):ii2-i34.  https://doi.org/10.1136/annrheumdis-2013-203348
  32. Ng CC, Sy A, Cunningham ET Jr. Rituximab for non-infectious Uveitis and Scleritis. J Ophthalm Inflamm Infect. 2021;11(1):23.  https://doi.org/10.1186/s12348-021-00252-4
  33. Ng CC, Sy A, Cunningham ET Jr. Rituximab for treatment of non- infectious and non-malignant orbital inflammatory disease. J Ophthalm Inflamm Infect. 2021;11(1):24.  https://doi.org/10.1186/s12348-021-00253-3
  34. Ciccia F, Guggino G, Rizzo A, Alessandro R, Carubbi F, Giardina A, et al. Rituximab Modulates IL-17 Expression in the Salivary Glands of Patients with Primary Sjögren’s Syndrome. Rheumatology (Oxford). 2014;53(7):1313-1320. https://doi.org/10.1093/rheumatology/keu004
  35. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot J-M, Perdriger A, Puéchal X, Guern VL, Sibilia J, Gottenberg J-E, Chiche L, Hachulla E, Hatron PY, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Pers JO, Nowak E, Saraux A. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160(4):233-242.  https://doi.org/10.7326/M13-1085
  36. Meijer JM, Meiners PM, Vissink A, Spijkervet FKL, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CGM, Bootsma H. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(4):960-968.  https://doi.org/10.1002/art.27314
  37. Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A, Chams-Davatchi C, et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13(3):246-252.  https://doi.org/10.1111/j.1756-185X.2010.01546.x
  38. Hickman RA, Denniston AK, Yee CS, Toescu V, Murray PI, Gordon C. Bilateral retinal vasculitis in a patient with systemic lupus erythematosus and its remission with rituximab therapy. Lupus. 2010;19(3):327-329.  https://doi.org/10.1177/0961203309347332
  39. Paley MA, Karacal H, Rao PK, Margolis TP, Miner JJ. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2018;13:53-55.  https://doi.org/10.1016/j.ajoc.2018.12.001
  40. Miserocchi E, Giuffrè C, Cornalba M, Pontikaki I, Cimaz R. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39(3):847-851.  https://doi.org/10.1007/s10067-019-04875-w
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.